Výsledky vyhledávání - "V. Abbadessa"

HIV infection: oral lesions, CD4 + cell count and viral load in an ltalian study population

Autor: Vincenzo Accurso, Valerio Margiotta, V. Abbadessa, Giuseppina Campisi, Salvatrice Mancuso

Publikováno v: Journal of Oral Pathology & Medicine. 28:173-177

The aims of this study were to assess types and prevalence of HIV-related oral lesions and to correlate these lesions to the main laboratory parameters such as CD4+ cell count and plasma HIV-RNA. The study population consisted of 104 consecutive HIV+

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01d5464e5b75bc03f83bccd6b8325e0a
https://doi.org/10.1111/j.1600-0714.1999.tb02019.x

Zobrazit plný text záznamu

[The use of hyperimmune anti-cytomegalovirus immunoglobulins in HIV infection]

Autor: S, Mancuso, V, Abbadessa, R, Perricone, A, Cajozzo

Publikováno v: Recenti progressi in medicina. 87(6)

Cytomegalovirus (CMV) is one of the most frequent opportunistic agents that affects HIV positive subjects. The prophylaxis and treatment of cytomegalovirus infection in HIV positive subjects represent difficult and controversial problems. In this stu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::be36e60c7be25aac7334a3a844d5872d
https://pubmed.ncbi.nlm.nih.gov/8766951

Zobrazit plný text záznamu

Effects of R-enantiomer (GR66234A) and L-enantiomer (GR66235A) of telupidine, a new dihydropyridine derivative, on cell lines displaying the multidrug resistant phenotype

Autor: M, Tolomeo, R A, Gancitano, M, Musso, F, Porretto, R, Perricone, V, Abbadessa, A, Cajozzo

Publikováno v: Haematologica. 79(4)

Many dihydropyridine analogues with calcium channel blocker activity are able to reverse multidrug resistance (MDR). We studied the daunorubicin resistance reversing activity of the R enantiomer (GR66234A) and the L-enantiomer (GR66235 A) of teludipi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5fd4178d9abe40f9e3af351b7e208b1a
https://pubmed.ncbi.nlm.nih.gov/7806087

Zobrazit plný text záznamu

Selection of a new multidrug resistant cell line from Friend leukemia cells by short and cyclic exposures to high concentrations of daunorubicin

Autor: V, Abbadessa, M, Tolomeo, M, Luparello, R, Perricone, A, Cajozzo, L, Dusonchet, V, Candiloro, L, Crosta, L, Rausa

Publikováno v: Haematologica. 77(2)

Resistance of tumor cells to cytotoxic agents can be due to the overexpression of the mdr 1 gene, which encodes a plasma membrane protein (P-glycoprotein). To understand the molecular basis of multidrug resistance, several laboratories have isolated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d03ee6a7feea203211ac714e2046611b
https://pubmed.ncbi.nlm.nih.gov/1356894

Zobrazit plný text záznamu

ProMACE-cytaBOM versus MACOP-B in intermediate and high grade NHL. Preliminary results of a prospective randomized trial

Autor: M, Federico, G, Moretti, P G, Gobbi, P, Avanzini, L, Cavanna, M, Carotenuto, M, Lombardo, G, Leone, V, Pitini, V, Abbadessa

Publikováno v: Leukemia. 5

One hundred seventy-nine patients with intermediate or high-grade non-Hodgkin's lymphoma were randomized to receive either ProMACE-CytaBOM (P-C) or MACOP-B (M-B). At last follow-up 71 patients in the P-C arm and 78 in the M-B arm were assessable for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1c0868dccb2d8aba8ba6a4c59c540834
https://pubmed.ncbi.nlm.nih.gov/1716340

Zobrazit plný text záznamu

[Potentiation of the antiblastic activity of mafosfamide by GM-CSF and interleukin-3: a possible use in the treatment of acute myeloblastic leukemia]

Autor: M, Tolomeo, M, Luparello, E, Caravello, M, Musso, V, Abbadessa, R, Perricone, A, Cajozzo

Publikováno v: Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna. 5(4 Pt 1)

The low activity of antiblastic drugs on tumor cells in the G0 phase is an important limitation in the therapy of malignancies. Cells in the G0 phase are able to enter in cycle any time after chemotherapy treatment, causing relapse of the disease. Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::329378a94e63a3bc3254a6e199bc9bd3
https://pubmed.ncbi.nlm.nih.gov/2093359

Zobrazit plný text záznamu

[Use of immunoglobulins in AIDS]

Autor: V, Accurso, S, Mancuso, M E, Mitra, E, Caravello, V, Abbadessa, A, Cajozzo

Publikováno v: Recenti progressi in medicina. 81(7-8)

Fourteen AIDS patients with constitutional symptoms without a known etiology were treated with intravenous immunoglobulins (IVIG). The dosage regimen was 300 mg/kg per day three times weekly for two weeks followed by 300 mg/kg per day once weekly for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d3ec6482d972f39826b9eaeec7a90469
https://pubmed.ncbi.nlm.nih.gov/2247698

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání